Theranostics 2021; 11(11):5430-5446. doi:10.7150/thno.53961 This issue Cite

Review

Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases

Danqi Li1,2*, Yuchen Lou1,2*, Yamin Zhang1,2, Si Liu3, Jun Li4✉, Juan Tao1,2✉

1. Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2. Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China.
3. Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
4. Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
*These authors contributed equally to this work.

Citation:
Li D, Lou Y, Zhang Y, Liu S, Li J, Tao J. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics 2021; 11(11):5430-5446. doi:10.7150/thno.53961. https://www.thno.org/v11p5430.htm
Other styles

File import instruction

Abstract

Graphic abstract

Human immunoglobulin G (IgG), especially autoantibodies, has major implications for the diagnosis and management of a wide range of autoimmune diseases. However, some healthy individuals also have autoantibodies, while a portion of patients with autoimmune diseases test negative for serologic autoantibodies. Recent advances in glycomics have shown that IgG Fc N-glycosylations are more reliable diagnostic and monitoring biomarkers than total IgG autoantibodies in a wide variety of autoimmune diseases. Furthermore, these N-glycosylations of IgG Fc, particularly sialylation, have been reported to exert significant anti-inflammatory effects by upregulating inhibitory FcγRIIb on effector macrophages and reducing the affinity of IgG for either complement protein or activating Fc gamma receptors. Therefore, sialylated IgG is a potential therapeutic strategy for attenuating pathogenic autoimmunity. IgG sialylation-based therapies for autoimmune diseases generated through genetic, metabolic or chemoenzymatic modifications have made some advances in both preclinical studies and clinical trials.

Keywords: sialylation, immunoglobulin G, glycosylation, autoimmune diseases, precision medicine


Citation styles

APA
Li, D., Lou, Y., Zhang, Y., Liu, S., Li, J., Tao, J. (2021). Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics, 11(11), 5430-5446. https://doi.org/10.7150/thno.53961.

ACS
Li, D.; Lou, Y.; Zhang, Y.; Liu, S.; Li, J.; Tao, J. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics 2021, 11 (11), 5430-5446. DOI: 10.7150/thno.53961.

NLM
Li D, Lou Y, Zhang Y, Liu S, Li J, Tao J. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics 2021; 11(11):5430-5446. doi:10.7150/thno.53961. https://www.thno.org/v11p5430.htm

CSE
Li D, Lou Y, Zhang Y, Liu S, Li J, Tao J. 2021. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics. 11(11):5430-5446.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image